Amgen

This study tests whether olpasiran can reduce major heart problems like heart attacks and urgent procedures in people with high levels of lipoprotein(a), a genetic risk factor for heart disease. About 7,300 adults with existing heart disease and elevated Lp(a) are randomly assign…

This study tests a drug called blinatumomab in Chinese children (ages 1 month to 18 years) whose B-cell acute lymphoblastic leukemia has come back or not responded to standard treatment. The goal is to see if the drug can bring about a complete remission. The trial involves 18 pa…

This study tests whether XGEVA (Denosumab) can shrink or control giant cell tumor of bone (GCTB) in Chinese adults and teens aged 12 and older. GCTB is a rare, usually non-cancerous bone tumor that can cause pain and damage. The main goal is to see how many patients have their tu…

This study tests a new medication called maridebart cafraglutide in 409 adults with type 2 diabetes. The goal is to see if it improves blood sugar levels and helps with weight loss compared to a placebo. Participants must have had diabetes for at least 6 months and be on diet/exe…

This study tests whether the drug apremilast can safely and effectively treat moderate to severe plaque psoriasis in Japanese children and teens aged 6 to 17. Participants take the medication and are monitored for skin clearing and side effects. The goal is to control the disease…

This study compares a new drug, xaluritamig, with two standard treatments (cabazitaxel or another hormone therapy) in 707 men with metastatic castration-resistant prostate cancer who have already had chemotherapy. The main goal is to see if xaluritamig helps people live longer. P…

This early-stage study tests a drug called tarlatamab in about 269 people with small cell lung cancer that has come back or not responded to standard treatment. The main goal is to check the drug's safety and how the body processes it. Researchers will monitor side effects and me…

This study tests a new drug called maridebart cafraglutide to help adults in Japan with obesity lose weight. About 279 participants will receive either the drug or a placebo for 72 weeks. The main goals are to see how much weight they lose and if at least 5% of body weight is los…

This study tests a new way to give the drug blinatumomab (under the skin, like a shot) to children under 12 with a type of leukemia that has come back or not responded to treatment. The goal is to see if this method is safe and can help get rid of the cancer. About 104 children w…

This study tests an experimental drug called dazodalibep in 651 people with Sjögren's syndrome who have moderate-to-severe disease activity. The goal is to see if the drug can reduce overall disease activity and improve symptoms like dryness, compared to a placebo. Participants w…

This study is checking the long-term safety of a drug called rocatinlimab for people with moderate-to-severe eczema (atopic dermatitis). It involves over 2,600 adults and teens who have already completed a previous rocatinlimab study. Researchers will monitor side effects and see…

This phase 3 study compares the experimental drug tarlatamab to standard treatments in 509 adults with small cell lung cancer that returned after initial chemotherapy. The main goal is to see if tarlatamab helps people live longer. Participants must have measurable disease and ha…

This study tests different doses of tarlatamab in 252 adults with small cell lung cancer that has worsened after one round of chemotherapy. The goal is to see if the drug can shrink tumors or stop the cancer from growing. Tarlatamab is an immunotherapy that helps the immune syste…

This study tests a drug called sotorasib in people with advanced solid tumors that have a specific KRAS gene mutation. The goal is to find the safest dose and see if the drug can shrink tumors. About 713 adults with various cancers, including lung cancer, are taking part.

This study tests a new drug called tarlatamab combined with standard chemotherapy and an immunotherapy for people with extensive stage small cell lung cancer who have not had prior treatment. The main goal is to check the safety and side effects of this combination. About 184 adu…

This study tests a drug called inebilizumab to see if it can prevent flare-ups in people with IgG4-related disease, a rare condition that causes swelling and damage in multiple organs. About 135 adults who have had a recent flare and need steroid treatment are participating. The …

This study tests whether giving evolocumab, a powerful cholesterol-lowering drug, very early during a heart attack hospital stay can reduce the chance of another heart attack, stroke, or death. About 6000 adults hospitalized for a heart attack took part. The drug is added to stan…

This study tests a new medication, maridebart cafraglutide, to help adults with type 2 diabetes who are overweight or obese lose weight. About 1,100 participants will receive either the drug or a placebo for 72 weeks. The main goal is to see how much weight they lose and if it im…

This study compares a new targeted therapy, AMG 510, to standard chemotherapy (docetaxel) in people with a specific type of advanced lung cancer (KRAS G12C mutation) that has already been treated. About 345 adults with locally advanced or metastatic non-small cell lung cancer are…

This study looks at the long-term safety of the drug inebilizumab in people with NMOSD, a rare autoimmune disease that affects the nerves. Researchers will measure immune cells and antibody levels in 32 adults who have already been on the drug for at least two years. The goal is …

This study compares a new drug, ABP 234, to the standard cancer treatment Keytruda (pembrolizumab) in people with advanced or spreading non-squamous non-small cell lung cancer who have not had prior treatment. The main goal is to see if ABP 234 works similarly in the body. About …

This early-stage study tests a new treatment called AMG 119 for adults with small cell lung cancer that has returned or not responded to standard chemotherapy. The treatment uses specially engineered immune cells (CAR T cells) to attack the cancer. The main goals are to check saf…

This study tests an experimental drug called rocatinlimab in 317 adults with moderate-to-severe asthma. The goal is to see if it can reduce the number of asthma attacks when added to standard inhaler therapy. Participants receive either the drug or a placebo, and researchers trac…

This study tests a drug called inebilizumab in 238 adults with myasthenia gravis, a condition that causes muscle weakness. The goal is to see if it improves daily activities and muscle function compared to a placebo. Participants receive the drug or placebo for 26 weeks, with an …

This study tests a new drug called bemarituzumab combined with other cancer treatments for people with advanced stomach or gastroesophageal junction cancer that cannot be cured by surgery. The goal is to see if the combination is safe and helps shrink tumors. About 72 adults will…

This study compares a new drug, ABP 234, to the approved immunotherapy Keytruda (pembrolizumab) in 163 adults with early-stage non-squamous non-small cell lung cancer. Participants receive the drug after surgery and chemotherapy to help prevent cancer from coming back. The main g…

This study tests whether adding the drug bemarituzumab to standard chemotherapy and immunotherapy helps people with advanced stomach or gastroesophageal junction cancer live longer. The trial includes about 515 adults whose tumors have a specific protein called FGFR2b. The goal i…

This early-stage study tests a new drug called AMG 355, alone or with another drug (pembrolizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Ab…

This study tests whether adding tarlatamab to durvalumab helps people with extensive-stage small-cell lung cancer live longer. About 563 adults who finished initial chemotherapy and durvalumab without their cancer getting worse will be randomly assigned to get either the combinat…

This study tests a drug called tarlatamab in people with limited-stage small cell lung cancer whose cancer has not grown after standard chemotherapy and radiation. About 404 participants will receive either tarlatamab or a placebo to see if the drug can delay cancer progression a…

This study tests whether a new drug called ABP 206 works as well as the approved drug OPDIVO (nivolumab) for people with advanced melanoma that cannot be removed by surgery or has spread. About 633 adults who have not had prior treatment for their advanced melanoma will receive e…

This study looks at how well the drug Prolia works and how safe it is for men with osteoporosis in mainland China. About 102 men aged 30 to 90 with low bone density or a history of fractures will receive Prolia injections. The main goal is to see if bone density in the lower spin…

This study tests an injected drug called teprotumumab in people with moderate-to-severe active thyroid eye disease, a condition that causes eye bulging, redness, and discomfort. About 89 adults will receive either the drug or a placebo to see if it safely reduces eye bulging by a…

This early-stage study tests a combination of three drugs (tarlatamab, YL201, and an anti-PD-L1) in about 200 adults with extensive stage small cell lung cancer that has worsened after initial treatment. The main goal is to check safety and side effects, while also measuring how …

This study tests a new drug called anvumetostat, alone or with chemotherapy (docetaxel), in adults whose advanced solid tumors lack a gene called MTAP. The goal is to find safe doses and see if the drug shrinks tumors. About 329 people will take part across multiple phases.

This study tests a new drug called maridebart cafraglutide to help adults with obesity or overweight lose weight. About 3853 people took the drug or a placebo for 72 weeks. The main goal is to see how much weight they lose and if it is safe.

This study tests a drug called tarlatamab in 32 Chinese adults with advanced small cell lung cancer that has worsened after at least two prior treatments. The main goal is to see if the drug can shrink tumors. This is a Phase 2a trial, meaning it's still early, and the drug aims …

This study tests a drug called sotorasib, alone or with other cancer treatments, in adults with advanced solid tumors that have a specific KRAS G12C gene change. The main goals are to check safety and how well the drug works at shrinking or controlling tumors. About 610 participa…

This study tests an experimental drug called tarlatamab in 222 adults with small cell lung cancer that has come back or not responded to at least two prior treatments. The main goals are to see if the drug shrinks tumors and to check its safety. Participants receive tarlatamab at…

This study tests a new drug called xaluritamig in about 50 men whose prostate cancer has returned after surgery or radiation but has not spread. The main goal is to check the drug's safety and side effects. Researchers will also measure how well it controls PSA levels, a marker o…

This study tests whether adding the drug bemarituzumab to standard chemotherapy helps people with advanced stomach or gastroesophageal junction cancer live longer. The trial includes about 547 adults whose tumors have high levels of a protein called FGFR2b. Participants receive e…

This study tests a drug called romiplostim in 145 adults with lung, ovarian, or breast cancer who have low platelets from chemotherapy. The goal is to see if it helps them get their full chemo doses on time without delays or reductions. Romiplostim works by boosting platelet prod…

This study looks at how safe the drug apremilast is for children and teens aged 6 to 17 with mild to moderate plaque psoriasis. About 51 participants will take the drug and be monitored for side effects, growth, and development. The goal is to make sure the treatment is safe for …

This study tests a drug called dazodalibep in 434 adults with moderate-to-severe Sjögren's syndrome, a condition causing dry eyes, dry mouth, and fatigue. Participants receive either the drug or a placebo to see if it improves symptoms like dryness and tiredness. The goal is to f…

This study tests a new medicine called rocatinlimab for adults with prurigo nodularis, a condition causing intense itching and hard bumps on the skin. Participants must have at least 20 nodules and not have gotten relief from creams or ointments. The goal is to see if the drug re…

This study tests whether the drug erenumab can prevent migraines in children (ages 6 to under 12) and adolescents (12 to under 18) who have episodic migraines. About 457 participants will receive either erenumab or a placebo. The main goal is to see if the drug reduces the number…

This early-stage study compares how two different injection versions of the experimental drug maridebart cafraglutide are absorbed by the body. About 348 adults with overweight or obesity will receive a single dose of one version. The main goal is to measure drug levels in the bl…

This early-stage study tests how the body absorbs an experimental weight-loss drug, maridebart cafraglutide, when given as two different types of injections. About 349 adults with overweight or obesity will receive a single dose to compare drug levels and check for side effects. …

This early-stage study checks whether maridebart cafraglutide, a drug for overweight or obesity, changes the heart's electrical activity. About 81 adults aged 18-60 will receive the drug, a placebo, or a positive control to compare effects. The main goal is to see if the drug cau…